A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
Status:
Withdrawn
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy of loading doses of intravenous Bondronat in
reducing pain in patients with breast cancer and metastatic bone disease experiencing
moderate to severe bone pain. Patients will receive an intravenous infusion of 6mg Bondronat
on days 1, 2 and 3. The anticipated time on study treatment is <3 months, and the target
sample size is <100 individuals.